Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

QLT Divests U.S. Business, Retains Wet AMD Treatment Visudyne

This article was originally published in The Pink Sheet Daily

Executive Summary

Following a strategic review of its assets, Canadian company divests its only other marketed product, prostate cancer drug Eligard, and lays off 115 employees.
Advertisement

Related Content

Medical Device Market & Industry Briefs, August 2012
Retaane Fails Again In Macular Degeneration
Retaane Fails Again In Macular Degeneration
Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch
Allergan Acquires QLT’s Aczone, Plans Fourth Quarter Launch
Novartis To Acquire Majority Stake In Alcon
Novartis To Acquire Majority Stake In Alcon
QLT May Divest Products Or Place Entire Company Up For Sale
QLT May Divest Products Or Place Entire Company Up For Sale
QLT Asks FDA To Remove Blood Screening Requirement For Acne Treatment Aczone

Topics

Advertisement
UsernamePublicRestriction

Register

PS066743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel